Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

IGF-1 LR3 vs PEG-MGF

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

This combination is flagged

Two IGF-1 analogs in the same regimen: Moderate-High risk per peptide research literature. Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.

Data-derived verdict

IGF-1 LR3 has stronger documented evidence (Anecdotal + Animal Studies) than PEG-MGF (Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 LR3 is the safer pick. PEG-MGF may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

IGF-1 LR3

Anecdotal + Animal Studies

PEG-MGF

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

IGF-1 LR3 PEG-MGF
Class IGF-1 analog (extended half-life); anabolic Pegylated IGF-1 splice variant; anabolic
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism IGF-1 receptor agonist; Arg3 substitution reduces IGFBP binding for prolonged activity PEG conjugation extends half-life of MGF for systemic action
Route SC / IM SC / IM
Half-life ~20-30 hrs ~2-3 days
Dosage (research) 20 mcg SC daily (Seeds Vol 1 endurance and recovery starting dose, range up to 100 mcg/day for hypertrophy per r/Peptides wiki) 200-400 mcg SC 1-2x weekly
Evidence tier Anecdotal + Animal Studies Anecdotal
Research depth 34 indexed (PubMed 15 · CT 0 · EPMC 19) 1 indexed (PubMed 0 · CT 0 · EPMC 1)
Availability Research Chemical Research Chemical
Reported risks Hypoglycemia risk; theoretical cancer risk; disproportional organ/tissue growth Immunogenicity concerns with PEG; limited safety data

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick IGF-1 LR3 or PEG-MGF?

IGF-1 LR3 has stronger documented evidence (Anecdotal + Animal Studies) than PEG-MGF (Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 LR3 is the safer pick. PEG-MGF may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between IGF-1 LR3 and PEG-MGF?

IGF-1 LR3 is classed as IGF-1 analog (extended half-life); anabolic; PEG-MGF is classed as Pegylated IGF-1 splice variant; anabolic. Reported mechanism: IGF-1 LR3, IGF-1 receptor agonist; Arg3 substitution reduces IGFBP binding for prolonged activity; PEG-MGF, PEG conjugation extends half-life of MGF for systemic action. Reported half-life: IGF-1 LR3, ~20-30 hrs; PEG-MGF, ~2-3 days. Routes in published studies: IGF-1 LR3, SC / IM; PEG-MGF, SC / IM.

Which has stronger evidence, IGF-1 LR3 or PEG-MGF?

IGF-1 LR3 and PEG-MGF sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. IGF-1 LR3 is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 34 indexed studies. PEG-MGF is graded Anecdotal, with 1 cited source on its reference page and 1 indexed studies.

Which is more accessible, IGF-1 LR3 or PEG-MGF?

Neither IGF-1 LR3 nor PEG-MGF is an FDA-approved drug. Catalog status: IGF-1 LR3, Research Chemical; PEG-MGF, Research Chemical. PEG-MGF's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are IGF-1 LR3 and PEG-MGF ever combined?

IGF-1 LR3 and PEG-MGF appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two IGF-1 analogs in the same regimen, moderate-high risk.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…